• 1
    Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. HEPATOLOGY 2002; 35: 497499.
  • 2
    Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004; 53: 28552860.
  • 3
    Lee DH, Silventoinen K, Jacobs DR Jr, Jousilahti P, Tuomileto J. γ-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004; 89: 54105414.
  • 4
    Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47: 13601369.
  • 5
    Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 2006; 22: 437443.
  • 6
    Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87: 30233028.
  • 7
    Tripathy D, Almgren P, Tuomi T, Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004; 27: 22042210.
  • 8
    Kilpatrick ES, Dominiczak MH, Small M. The effects of ageing on glycation and the interpretation of glycaemic control in Type 2 diabetes. QJM 1996; 89: 307312.
  • 9
    Rohlfing CL, Little RR, Wiedmeyer HM, England JD, Madsen R, Harris MI, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000; 23: 187191.
  • 10
    Bouma M, Dekker JH, de Sonnaville JJ, van der Does FE, de VH, Kriegsman DM, et al. How valid is fasting plasma glucose as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes? Diabetes Care 1999; 22: 904907.
  • 11
    Landgraf R. The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev 2004; 20(Suppl 2): S9S12.
  • 12
    Simon D, Senan C, Garnier P, Saint-Paul M, Papoz L. Epidemiological features of glycated haemoglobin A1c-distribution in a healthy population. The Telecom Study. Diabetologia 1989; 32: 864869.
  • 13
    Ishizaka N, Ishizaka Y, Takahashi E, Unuma T, Tooda Ei, Nagai R, et al. Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance. arterioscler thromb vasc Biol 2003; 23: 295301.
  • 14
    Lawlor DA, Ebrahim S, Davey Smith G. The association between components of adult height and Type II diabetes and insulin resistance: British Women's Heart and Health Study. Diabetologia 2002; 45: 10971106.
  • 15
    Lawlor DA, Bedford C, Taylor M, Ebrahim S. Geographical variation in cardiovascular disease, risk factors, and their control in older women: British Women's Heart and Health Study. J Epidemiol Community Health 2003; 57: 134140.
  • 16
    World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organisation, 1999.
  • 17
    Flint AJ, Rimm EB. Commentary: Obesity and cardiovascular disease risk among the young and old–is BMI the wrong benchmark? Int J Epidemiol 2006; 35: 187189.
  • 18
    Lawlor DA, Sattar N, Davey Smith G, Ebrahim S. The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase. Am J Epidemiol 2005; 161: 10811088.
  • 19
    Lawlor DA, Davey Smith G, Patel R, Ebrahim S. Life-Course Socioeconomic Position, Area Deprivation, and Coronary Heart Disease: Findings From the British Women's Heart and Health Study. Am J Public Health 2005; 95: 9197.
  • 20
    Andersen L, Dinesen B, Jorgensen PN, Poulsen F, Roder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 1993; 39: 578582.
  • 21
    Lawlor DA, Davey Smith G., Ebrahim S. Life course influences on insulin resistance: findings from the British Women's Heart and Health Study. Diabetes Care 2003; 26: 97103.
  • 22
    May M, Lawlor DA, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women — can we improve on Framingham?: British Women's Heart and Health prospective cohort study. Heart 2006; 92: 13961401.
  • 23
    Pietilainen KH, Rissanen A, Kaprio J, Makimattila S, Hakkinen AM, Westerbacka J, et al. Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab 2005; 288: E768E774.
  • 24
    Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 110.
  • 25
    Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. HEPATOLOGY 2005; 41: 11511159.
  • 26
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412419.
  • 27
    Harris EH. Elevated Liver Function Tests in Type 2 Diabetes. Clin Diabetes 2005; 23: 115119.
  • 28
    Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 11291133.
  • 29
    Kim DJ, Noh JH, Cho NH, Lee BW, Choi YH, Jung JH, et al. Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med 2005; 22: 11341140.
  • 30
    Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000; 49: 749758.
  • 31
    Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 18891895.
  • 32
    Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease. J Biol Chem 2004; 279: 3234532353.
  • 33
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 18441850.
  • 34
    Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. HEPATOLOGY 2002; 35: 367372.
  • 35
    Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 319.
  • 36
    Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001; 44: 929945.
  • 37
    Monnier L, Colette C, Thuan JF, Lapinski H. Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. Eur J Clin Invest 2006; 36: 231235.
  • 38
    Le Roith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 2006; 113: 3s11s.
  • 39
    Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 2003; 52: 701707.
  • 40
    Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634642.
  • 41
    Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. HEPATOLOGY 2005; 41: 6471.
  • 42
    Andre P, Balkau B, Born C, Royer B, Wilpart E, Charles MA, et al. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes Metab 2005; 31: 542550.
  • 43
    Teo CG. Molecular epidemiology of hepatitis B in England and Wales. J Clin Virol 2005; 34(Suppl 1): S13S14.
  • 44
    Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45: 219226.
  • 45
    Allen K, Williamson R. Screening for hereditary haemochromatosis should be implemented now. BMJ 2000; 320: 183184.